Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Jan;37(1):1–7. doi: 10.1128/aac.37.1.1

Use of rifampin in nonstaphylococcal, nonmycobacterial disease.

A B Morris 1, R B Brown 1, M Sands 1
PMCID: PMC187595  PMID: 8431003

Abstract

Rifampin has very broad antimicrobial properties with in vitro activities against many bacteria, mycobacteria, higher bacteria, chlamydia, fungi, parasites, and viruses (Table 1). The clinical use of rifampin is more limited, in part because of the lack of in vivo human clinical studies demonstrating its efficacy. Investigators have valid concerns regarding the emergence of resistance of mycobacteria if widespread use of rifampin becomes common, although this has not been well documented. Because rifampin obtains therapeutic levels intracellularly and is distributed widely throughout the body, the antibiotic potentially could be used on a broader scale, but more studies will be needed to demonstrate its clinical utility.

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acar J. F., Goldstein F. W., Duval J. Use of rifampin for the treatment of serious staphylococcal and gram-negative bacillary infections. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S502–S506. doi: 10.1093/clinids/5.supplement_3.s502. [DOI] [PubMed] [Google Scholar]
  2. Acocella G., Arioli V. Pseudomembranous colitis and rifampicin. Lancet. 1980 Apr 12;1(8172):827–828. doi: 10.1016/s0140-6736(80)91330-6. [DOI] [PubMed] [Google Scholar]
  3. Ariza J., Gudiol F., Pallarés R., Rufí G., Fernández-Viladrich P. Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis. Antimicrob Agents Chemother. 1985 Oct;28(4):548–551. doi: 10.1128/aac.28.4.548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bachs L., Parés A., Elena M., Piera C., Rodés J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet. 1989 Mar 18;1(8638):574–576. doi: 10.1016/s0140-6736(89)91608-5. [DOI] [PubMed] [Google Scholar]
  5. Beggs W. H., Sarosi G. A., Andrews F. A. Synergistic action of amphotericin B and rifampin on Candida albicans. Am Rev Respir Dis. 1974 Nov;110(5):671–673. doi: 10.1164/arrd.1974.110.5.671. [DOI] [PubMed] [Google Scholar]
  6. Belli L., Ambrona M. S., Gennaro E. A., Isola E. H., González Rescigno G. R. Acute gonococcal urethritis: treatment with a single dose of rifampicin. J Int Med Res. 1983;11(1):32–37. doi: 10.1177/030006058301100107. [DOI] [PubMed] [Google Scholar]
  7. Berkey P., Rolston K., Zukiwski A., Gooch G., Bodey G. P. Rifampin-resistant meningococcal infection in a patient given rifampin chemoprophylaxis. Am J Infect Control. 1988 Dec;16(6):250–252. doi: 10.1016/s0196-6553(88)80004-x. [DOI] [PubMed] [Google Scholar]
  8. Boakes A. J., Loo P. S., Ridgway G. L., Tovey S., Oriel J. D. Treatment of uncomplicated gonorrhoea in women with a combination of rifampicin and erythromycin. Br J Vener Dis. 1984 Oct;60(5):309–311. doi: 10.1136/sti.60.5.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Brook I. Penicillin V and rifampin for streptococcal pharyngitis. J Pediatr. 1985 Nov;107(5):825–826. doi: 10.1016/s0022-3476(85)80437-6. [DOI] [PubMed] [Google Scholar]
  10. Brozena S. J., Cohen L. E., Fenske N. A. Folliculitis decalvans--response to rifampin. Cutis. 1988 Dec;42(6):512–515. [PubMed] [Google Scholar]
  11. Brumfitt W., Dixson S., Hamilton-Miller J. M. Use of rifampin for the treatment of urinary tract infections. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S573–S582. doi: 10.1093/clinids/5.supplement_3.s573. [DOI] [PubMed] [Google Scholar]
  12. Buggy B. P., Fekety R., Silva J., Jr Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol. 1987 Apr;9(2):155–159. doi: 10.1097/00004836-198704000-00009. [DOI] [PubMed] [Google Scholar]
  13. Burghouts J., Haanen C. A possible role of rifampicin in prolonging remission duration in acute myelogenous leukaemia. Scand J Haematol. 1986 Apr;36(4):376–378. doi: 10.1111/j.1600-0609.1986.tb01752.x. [DOI] [PubMed] [Google Scholar]
  14. Chandrika T., Adler S. P. A case of neonatal meningitis due to Flavobacterium meningosepticum successfully treated with rifampin. Pediatr Infect Dis. 1982 Jan-Feb;1(1):40–41. doi: 10.1097/00006454-198201000-00012. [DOI] [PubMed] [Google Scholar]
  15. Chaudhary S., Bilinsky S. A., Hennessy J. L., Soler S. M., Wallace S. E., Schacht C. M., Bisno A. L. Penicillin V and rifampin for the treatment of group A streptococcal pharyngitis: a randomized trial of 10 days penicillin vs 10 days penicillin with rifampin during the final 4 days of therapy. J Pediatr. 1985 Mar;106(3):481–486. doi: 10.1016/s0022-3476(85)80687-9. [DOI] [PubMed] [Google Scholar]
  16. Chin N. X., Neu H. C. Synergy of imipenem--a novel carbapenem, and rifampin and ciprofloxacin against Pseudomonas aeruginosa, Serratia marcescens and Enterobacter species. Chemotherapy. 1987;33(3):183–188. doi: 10.1159/000238493. [DOI] [PubMed] [Google Scholar]
  17. Colebunders R., Ursi J. P., Pattyn S., Snoeck J. Prosthetic valve endocarditis due to methicillin-resistant Staphylococcus epidermidis and Micrococcus species successfully treated with rifampicin combined with other antibiotics. J Infect. 1985 Jul;11(1):35–39. doi: 10.1016/s0163-4453(85)90954-5. [DOI] [PubMed] [Google Scholar]
  18. Colmenero Castillo J. D., Hernandez Marquez S., Reguera Iglesias J. M., Cabrera Franquelo F., Rius Diaz F., Alonso A. Comparative trial of doxycycline plus streptomycin versus doxycycline plus rifampin for the therapy of human brucellosis. Chemotherapy. 1989;35(2):146–152. doi: 10.1159/000238662. [DOI] [PubMed] [Google Scholar]
  19. Conti R., Parenti F. Rifampin therapy for brucellosis, flavobacterium meningitis, and cutaneous leishmaniasis. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S600–S605. doi: 10.1093/clinids/5.supplement_3.s600. [DOI] [PubMed] [Google Scholar]
  20. Cooper E. R., Ellison R. T., 3rd, Smith G. S., Blaser M. J., Reller L. B., Paisley J. W. Rifampin-resistant meningococcal disease in a contact patient given prophylactic rifampin. J Pediatr. 1986 Jan;108(1):93–96. doi: 10.1016/s0022-3476(86)80776-4. [DOI] [PubMed] [Google Scholar]
  21. Coufalik E. D., Taylor-Robinson D., Csonka G. W. Treatment of nongonococcal urethritis with rifampicin as a means of defining the role of Ureaplasma urealyticum. Br J Vener Dis. 1979 Feb;55(1):36–43. doi: 10.1136/sti.55.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Darougar S., Viswalingam N., El-Sheikh H., Hunter P. A., Yearsley P. A double-blind comparison of topical therapy of chlamydial ocular infection (TRIC infection) with rifampicin or chlortetracycline. Br J Ophthalmol. 1981 Aug;65(8):549–552. doi: 10.1136/bjo.65.8.549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Dawson C. R., Hoshiwara I., Daghfous T., Messadi M., Vastine D. W., Schachter J. Topical tetracycline and rifampicin therapy of endemic trachoma in Tunisia. Am J Ophthalmol. 1975 May;79(5):803–811. doi: 10.1016/0002-9394(75)90740-0. [DOI] [PubMed] [Google Scholar]
  24. Dougherty E. M., Weiner R. M., Vaughn J. L., Reichelderfer C. F. Rifampin inhibition of the occluded virus form of a nuclear polyhedrosis virus. Antimicrob Agents Chemother. 1982 Sep;22(3):527–530. doi: 10.1128/aac.22.3.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Edelstein P. H. Rifampin resistance of Legionella pneumophila is not increased during therapy for experimental Legionnaires disease: study of rifampin resistance using a guinea pig model of Legionnaires disease. Antimicrob Agents Chemother. 1991 Jan;35(1):5–9. doi: 10.1128/aac.35.1.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ernst J. D., Rusnak M., Sande M. A. Combination antifungal chemotherapy for experimental disseminated candidiasis: lack of correlation between in vitro and in vivo observations with amphotericin B and rifampin. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S626–S630. doi: 10.1093/clinids/5.supplement_3.s626. [DOI] [PubMed] [Google Scholar]
  27. Even-Paz Z., Weinrauch L., Livshin R., El-On J., Greenblatt C. L. Rifampicin treatment of cutaneous leishmaniasis. Int J Dermatol. 1982 Mar;21(2):110–112. doi: 10.1111/j.1365-4362.1982.tb00517.x. [DOI] [PubMed] [Google Scholar]
  28. Fekety R., O'Connor R., Silva J. Rifampin and pseudomembranous colitis. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S524–S527. doi: 10.1093/clinids/5.supplement_3.s524. [DOI] [PubMed] [Google Scholar]
  29. Fekety R., Silva J., Toshniwal R., Allo M., Armstrong J., Browne R., Ebright J., Rifkin G. Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. Rev Infect Dis. 1979 Mar-Apr;1(2):386–397. doi: 10.1093/clinids/1.2.386. [DOI] [PubMed] [Google Scholar]
  30. Fitzgeorge R. B., Baskerville A., Featherstone A. S. Treatment of experimental Legionnaires' disease by aerosol administration of rifampicin, ciprofloxacin, and erythromycin. Lancet. 1986 Mar 1;1(8479):502–503. doi: 10.1016/s0140-6736(86)92960-0. [DOI] [PubMed] [Google Scholar]
  31. Fu K. P., Lasinski E. R., Zoganas H. C., Kimble E. F., Konopka E. A. Efficacy of rifampicin in experimental Bacteroides fragilis and Pseudomonas aeruginosa mixed infections. J Antimicrob Chemother. 1985 May;15(5):579–585. doi: 10.1093/jac/15.5.579. [DOI] [PubMed] [Google Scholar]
  32. Fu K. P., Lasinski E. R., Zoganas H. C., Kimble E. F., Konopka E. A. Therapeutic efficacy and pharmacokinetic properties of rifampicin in a Bacteroides fragilis intra-abdominal abscess. J Antimicrob Chemother. 1984 Dec;14(6):633–640. doi: 10.1093/jac/14.6.633. [DOI] [PubMed] [Google Scholar]
  33. Gamea A. M. Local rifampicin in treatment of rhinoscleroma. J Laryngol Otol. 1988 Apr;102(4):319–321. doi: 10.1017/s0022215100104840. [DOI] [PubMed] [Google Scholar]
  34. Ghent C. N., Carruthers S. G. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology. 1988 Feb;94(2):488–493. doi: 10.1016/0016-5085(88)90442-8. [DOI] [PubMed] [Google Scholar]
  35. Gordon R. C., Wofford-McQueen R., Shu K. In vitro synergism of rifampin-cephalosporin combinations against Haemophilus influenzae type b. Eur J Clin Microbiol Infect Dis. 1990 Mar;9(3):201–205. doi: 10.1007/BF01963838. [DOI] [PubMed] [Google Scholar]
  36. Graybill J. R., Ahrens J. Interaction of rifampin with other antifungal agents in experimental murine candidiasis. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S620–S625. doi: 10.1093/clinids/5.supplement_3.s620. [DOI] [PubMed] [Google Scholar]
  37. Hart D. H., Peel M. M., Andrew J. H., Burdon J. G. Lung infection caused by Rhodococcus. Aust N Z J Med. 1988 Oct;18(6):790–791. doi: 10.1111/j.1445-5994.1988.tb00182.x. [DOI] [PubMed] [Google Scholar]
  38. Havlichek D., Pohlod D., Saravolatz L. Comparison of ciprofloxacin and rifampicin in experimental Legionella pneumophila pneumonia. J Antimicrob Chemother. 1987 Dec;20(6):875–881. doi: 10.1093/jac/20.6.875. [DOI] [PubMed] [Google Scholar]
  39. Hernández Pérez M. A., Anciones Rodriguez B., Garcia A. F., Diez-Tejedor E., Barreiro Tella P. Treatment of nervous system brucellosis with rifampin and doxycycline. Neurology. 1986 Oct;36(10):1408–1409. doi: 10.1212/wnl.36.10.1408-b. [DOI] [PubMed] [Google Scholar]
  40. Hillidge C. J. Use of erythromycin-rifampin combination in treatment of Rhodococcus equi pneumonia. Vet Microbiol. 1987 Aug;14(3):337–342. doi: 10.1016/0378-1135(87)90121-0. [DOI] [PubMed] [Google Scholar]
  41. Hirsh B. E., Wong B., Kiehn T. E., Gee T., Armstrong D. Flavobacterium meningosepticum bacteremia in an adult with acute leukemia. Use of rifampin to clear persistent infection. Diagn Microbiol Infect Dis. 1986 Jan;4(1):65–69. doi: 10.1016/0732-8893(86)90058-1. [DOI] [PubMed] [Google Scholar]
  42. Hughes W. T. Rifampicin for Pneumocystis carinii pneumonia. Lancet. 1983 Jul 16;2(8342):162–162. doi: 10.1016/s0140-6736(83)90143-5. [DOI] [PubMed] [Google Scholar]
  43. Jacobs F., Abramowicz D., Vereerstraeten P., Le Clerc J. L., Zech F., Thys J. P. Brucella endocarditis: the role of combined medical and surgical treatment. Rev Infect Dis. 1990 Sep-Oct;12(5):740–744. doi: 10.1093/clinids/12.5.740. [DOI] [PubMed] [Google Scholar]
  44. Jariwalla A. G., Davies B. H., White J. Infective endocarditis complicating psittacosis: response to rifampicin. Br Med J. 1980 Jan 19;280(6208):155–155. doi: 10.1136/bmj.280.6208.155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Jones R. B., Ridgway G. L., Boulding S., Hunley K. L. In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S556–S561. doi: 10.1093/clinids/5.supplement_3.s556. [DOI] [PubMed] [Google Scholar]
  46. Joshi R. K., Nambiar P. M. Dermal leishmaniasis and rifampicin. Int J Dermatol. 1989 Nov;28(9):612–614. doi: 10.1111/j.1365-4362.1989.tb02541.x. [DOI] [PubMed] [Google Scholar]
  47. Khuri-Bulos N. Meningococcal meningitis following rifampin prophylaxis. Am J Dis Child. 1973 Nov;126(5):689–691. doi: 10.1001/archpedi.1973.02110190553020. [DOI] [PubMed] [Google Scholar]
  48. Kim P. K., Kim K. S., Lee J. K., Lee J. S., Jeong H. J., Choi I. J. Rifampin therapy in Henoch-Schönlein purpura nephritis accompanied by nephrotic syndrome. Child Nephrol Urol. 1988;9(1-2):50–56. [PubMed] [Google Scholar]
  49. Kimbrough R. C., 3rd, Ormsbee R. A., Peacock M., Rogers W. R., Bennetts R. W., Raaf J., Krause A., Gardner C. Q fever endocarditis in the United States. Ann Intern Med. 1979 Sep;91(3):400–402. doi: 10.7326/0003-4819-91-3-400. [DOI] [PubMed] [Google Scholar]
  50. King J. W., White M. C. Pulmonary actinomycosis. Rapid improvement with isoniazid and rifampin. Arch Intern Med. 1981 Aug;141(9):1234–1235. doi: 10.1001/archinte.141.9.1234. [DOI] [PubMed] [Google Scholar]
  51. Korvick J. A., Peacock J. E., Jr, Muder R. R., Wheeler R. R., Yu V. L. Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: prospective trial using the Zelen protocol. Antimicrob Agents Chemother. 1992 Mar;36(3):620–625. doi: 10.1128/aac.36.3.620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Lazzarin A., Capsoni F., Tortorano A. M. Disseminated aspergillosis. Am J Dis Child. 1982 Jul;136(7):654–654. doi: 10.1001/archpedi.1982.03970430086035. [DOI] [PubMed] [Google Scholar]
  53. Levy H., Sacho H., Feldman C., Naude G. E., Peskin J., Stead K. J., Kallenbach J. M. Pulmonary mucormycosis presenting with Horner's syndrome. Report of a medical cure. S Afr Med J. 1986 Sep 13;70(6):363–365. [PubMed] [Google Scholar]
  54. Livshin R., Weinrauch L., Even-Paz Z., el-On J. Efficacy of rifampicin and isoniazid in cutaneous leishmaniasis. Int J Dermatol. 1987 Jan-Feb;26(1):55–59. doi: 10.1111/j.1365-4362.1987.tb04578.x. [DOI] [PubMed] [Google Scholar]
  55. Llorens-Terol J., Busquets R. M. Brucellosis treated with rifampicin. Arch Dis Child. 1980 Jun;55(6):486–488. doi: 10.1136/adc.55.6.486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Maduri-Traczewski M., Szymczak E. G., Goldmann D. A. In vitro activity of penicillin and rifampin against group B streptococci. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S586–S592. doi: 10.1093/clinids/5.supplement_3.s586. [DOI] [PubMed] [Google Scholar]
  57. McConkey B., Situnayake R. D. Effects of rifampicin with and without isoniazid in rheumatoid arthritis. J Rheumatol. 1988 Jan;15(1):46–50. [PubMed] [Google Scholar]
  58. Medoff G. Antifungal action of rifampin. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S614–S619. doi: 10.1093/clinids/5.supplement_3.s614. [DOI] [PubMed] [Google Scholar]
  59. Menke H. E., Schuller J. L., Stolz E., Niemel P. L., Michel M. F. Treatment of lymphogranuloma venereum with rifampicin. Br J Vener Dis. 1979 Oct;55(5):379–379. doi: 10.1136/sti.55.5.379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Moellering R. C., Jr, Wennersten C. Therapeutic potential of rifampin in enterococcal infections. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S528–S532. doi: 10.1093/clinids/5.supplement_3.s528. [DOI] [PubMed] [Google Scholar]
  61. Morrone N., De Castro Pereira C. A., Saito M., Dourado A. M., Pereira Da Silva Mendes E. S. Treatment of pulmonary actinomycosis with rifampin. G Ital Chemioter. 1982 Jul-Dec;29(2):121–124. [PubMed] [Google Scholar]
  62. Murdoch J. M., Speirs C. F., Wright N., Wallace E. T. Rifampicin. Lancet. 1969 May 31;1(7605):1094–1094. doi: 10.1016/s0140-6736(69)91725-5. [DOI] [PubMed] [Google Scholar]
  63. O'Connor R. P., Silva J., Jr, Fekety R. Rifampicin and antibiotic-associated colitis. Lancet. 1981 Feb 28;1(8218):499–499. doi: 10.1016/s0140-6736(81)91881-x. [DOI] [PubMed] [Google Scholar]
  64. Oriel J. D., Ridgway G. L., Goldmeier D., Felmingham D. Treatment of gonococcal urethritis in men with a rifampicin-erythromycin combination. Sex Transm Dis. 1982 Oct-Dec;9(4):208–211. doi: 10.1097/00007435-198210000-00011. [DOI] [PubMed] [Google Scholar]
  65. Panikabutra K., Ariyarit C., Chitwarakorn A., Wongba C. The combination of rifampicin-erythromycin in the treatment of gonococcal urethritis in men. J Med Assoc Thai. 1985 Nov;68(11):579–582. [PubMed] [Google Scholar]
  66. Peters W., Lainson R., Shaw J. J., Robinson B. L., Leão A. F. Potentiating action of rifampicin and isoniazid against Leishmania mexicana amazonensis. Lancet. 1981 May 23;1(8230):1122–1124. doi: 10.1016/s0140-6736(81)92296-0. [DOI] [PubMed] [Google Scholar]
  67. Plummer F. A., Nsanze H., D'Costa L. J., Ndugga Maggwa A. B., Girouard Y., Karasira P., Albritton W. L., Ronald A. R. Short-course and single-dose antimicrobial therapy for chancroid in Kenya: studies with rifampin alone and in combination with trimethoprim. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S565–S572. doi: 10.1093/clinids/5.supplement_3.s565. [DOI] [PubMed] [Google Scholar]
  68. Ribner B., Keusch G. T., Hanna B. A., Perloff M. Combination amphotericin B-rifampin therapy for pulmonary aspergillosis in a leukemic patient. Chest. 1976 Nov;70(5):681–683. doi: 10.1378/chest.70.5.681. [DOI] [PubMed] [Google Scholar]
  69. Rubin J., Stoehr G., Yu V. L., Muder R. R., Matador A., Kamerer D. B. Efficacy of oral ciprofloxacin plus rifampin for treatment of malignant external otitis. Arch Otolaryngol Head Neck Surg. 1989 Sep;115(9):1063–1069. doi: 10.1001/archotol.1989.01860330053016. [DOI] [PubMed] [Google Scholar]
  70. Ryan J. L., Pachner A., Andriole V. T., Root R. K. Enterococcal meningitis: combined vancomycin and rifampin therapy. Am J Med. 1980 Mar;68(3):449–451. doi: 10.1016/0002-9343(80)90118-7. [DOI] [PubMed] [Google Scholar]
  71. Saha S. K. Dermal leishmaniasis after kala-azar infection: successful treatment with rifampin. Cutis. 1985 Jul;36(1):81–82. [PubMed] [Google Scholar]
  72. Schachter J. Rifampin in chlamydial infections. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S562–S564. doi: 10.1093/clinids/5.supplement_3.s562. [DOI] [PubMed] [Google Scholar]
  73. Scheld W. M. Evaluation of rifampin and other antibiotics against Listeria monocytogenes in vitro and in vivo. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S593–S599. doi: 10.1093/clinids/5.supplement_3.s593. [DOI] [PubMed] [Google Scholar]
  74. Scheld W. M., Fletcher D. D., Fink F. N., Sande M. A. Response to therapy in an experimental rabbit model of meningitis due to Listeria monocytogenes. J Infect Dis. 1979 Sep;140(3):287–294. doi: 10.1093/infdis/140.3.287. [DOI] [PubMed] [Google Scholar]
  75. Shaffer J. L., Hughes S., Linaker B. D., Baker R. D., Turnberg L. A. Controlled trial of rifampicin and ethambutol in Crohn's disease. Gut. 1984 Feb;25(2):203–205. doi: 10.1136/gut.25.2.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Shehabi A., Shakir K., el-Khateeb M., Qubain H., Fararjeh N., Shamat A. R. Diagnosis and treatment of 106 cases of human brucellosis. J Infect. 1990 Jan;20(1):5–10. doi: 10.1016/s0163-4453(90)92214-6. [DOI] [PubMed] [Google Scholar]
  77. Singh B., Jones R. S. Treatment with rifampicin for Pneumocystis carinii pneumonia. Ann Trop Paediatr. 1984 Mar;4(1):49–50. doi: 10.1080/02724936.1984.11748306. [DOI] [PubMed] [Google Scholar]
  78. Sivonen A., Renkonen O. V., Weckström P., Koskenvuo K., Raunio V., Mäkelä P. H. The effect of chemoprophylactic use of rifampin and minocycline on rates of carriage of Neisseria meningitidis in army recruits in Finland. J Infect Dis. 1978 Mar;137(3):238–244. doi: 10.1093/infdis/137.3.238. [DOI] [PubMed] [Google Scholar]
  79. Subramanya N. I., Wright J. S., Khan M. A. Failure of rifampicin and co-trimoxazole in Q fever endocarditis. Br Med J (Clin Res Ed) 1982 Jul 31;285(6338):343–344. doi: 10.1136/bmj.285.6338.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Szychowska Z., Prandota-Schoepp A., Chabudzinska S. Rifampicin for Pneumocystic carinii pneumonia. Lancet. 1983 Apr 23;1(8330):935–935. doi: 10.1016/s0140-6736(83)91366-1. [DOI] [PubMed] [Google Scholar]
  81. Tanz R. R., Shulman S. T., Barthel M. J., Willert C., Yogev R. Penicillin plus rifampin eradicates pharyngeal carriage of group A streptococci. J Pediatr. 1985 Jun;106(6):876–880. doi: 10.1016/s0022-3476(85)80229-8. [DOI] [PubMed] [Google Scholar]
  82. Tuazon C. U., Lin M. Y., Sheagren J. N. In vitro activity of rifampin alone and in combination with nafcillin and Vancomycin against pathogenic strains of Staphylococcus aureus. Antimicrob Agents Chemother. 1978 May;13(5):759–761. doi: 10.1128/aac.13.5.759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Tuazon C. U., Shamsuddin D., Miller H. Antibiotic susceptibility and synergy of clinical isolates of Listeria monocytogenes. Antimicrob Agents Chemother. 1982 Mar;21(3):525–527. doi: 10.1128/aac.21.3.525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Vildé J. L., Dournon E., Rajagopalan P. Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents. Antimicrob Agents Chemother. 1986 Nov;30(5):743–748. doi: 10.1128/aac.30.5.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Vischer W. A., Rominger C. Rifampicin against experimental listeriosis in the mouse. Chemotherapy. 1978;24(2):104–111. doi: 10.1159/000237768. [DOI] [PubMed] [Google Scholar]
  86. Winslow D. L., Pankey G. A. Successful therapy with rifampin--flavobacterium meningosepticum meningitis developing while on erythromycin therapy. Del Med J. 1982 Oct;54(10):575–579. [PubMed] [Google Scholar]
  87. Wirostko E., Johnson L., Wirostko B. Crohn's disease. Rifampin treatment of the ocular and gut disease. Hepatogastroenterology. 1987 Apr;34(2):90–93. [PubMed] [Google Scholar]
  88. Yu V. L., Wagner G. E., Shadomy S. Sino-orbital aspergillosis treated with combination antifungal therapy. Successful therapy after failure with amphotericin B and surgery. JAMA. 1980 Aug 22;244(8):814–815. [PubMed] [Google Scholar]
  89. Zubovich I. K., Votiakov V. I., Mishaeva N. P., Saloilova T. I. Zashchitnoe deistvie rifampitsina pri éksperimental'noi rabicheskoi infektsii belykh myshei. Antibiot Khimioter. 1989 Feb;34(2):123–125. [PubMed] [Google Scholar]
  90. Zuravleff J. J., Chervenick P., Yu V. L., Muder R. R., Diven W. F. Addition of rifampin to ticarcillin-tobramycin combination for the treatment of Pseudomonas aeruginosa infections: assessment in a neutropenic mouse model. J Lab Clin Med. 1984 Jun;103(6):878–885. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES